Study with 283 patients, >1,000 plasma samples, and longest follow-up exceeding 5 years demonstrates how ctDNA monitoring can help inform treatment decisions in HR+/HER2- and TNBC patients
. | May 8, 2023
Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
A new genetic test that may allow patients with colorectal cancer to avoid chemotherapy after tumor resection is under investigation at AdventHealth Cancer Institute in Orlando, Florida.
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated. | April 18, 2023